Key clinical point: A retrospective study suggests venetoclax provides only modest benefit in patients with relapsed/refractory non-Hodgkin lymphomas (NHL).
Major finding: Among all evaluable patients, the overall response rate was 26%, with a median overall survival of 4.5 months and a progression-free survival of 2 months.
Study details: A retrospective analysis of 34 patients with NHL who received venetoclax, including 13 patients with high-grade B-cell lymphoma/ diffuse large B-cell lymphoma.
Disclosures: No funding sources were reported. The authors reported financial affiliations with Acerta Pharma, AstraZeneca, Celgene, Curis, Genentech, Gilead, Merck, Novartis, and several others.
Hughes ME et al. Clin Lymphoma Myeloma Leuk. 2019 Sep 28. doi: 10.1016/j.clml.2019.09.612.